Pharvaris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharvaris (PHVS).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

11Buy

1Hold

Consensus RatingOutperform# Analysts15Avg. Consensus PT$50Upside to Avg. PT+81.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$40→$44
Sep 9, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$46→$62
Sep 9, 2026	Leerink Partners	Joseph Schwartz	PT Raise	Outperform	$50→$65
Sep 9, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$55→$65
Sep 9, 2026	RBC Capital	Nevin Varghese	PT Raise	Outperform	$52→$62
Sep 9, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$75→$79
Sep 9, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$42→$50
Sep 8, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Sep 8, 2026	Wedbush	Laura Chico	Maintained	Outperform	$42
Aug 13, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$51→$52
Aug 13, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$39→$40
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$74→$75
Jul 15, 2026	Wells Fargo	Yanan Zhu	Initiate	Overweight	$55
Jun 25, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$41→$46
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$75→$74
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$42
Apr 7, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$41→$42
Apr 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$52→$51
Mar 9, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$52
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $40 to $44.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

Wells Fargo analyst Yanan Zhu maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $55 to $65.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62

RBC Capital analyst Nevin Varghese maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $52 to $62.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $75 to $79.

Benzinga Newsdesk

Pharvaris NV

Pharvaris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

PRO
Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

PRO
Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79

People Also Watch

People Also Watch

Pharvaris NV

Pharvaris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

PROMorgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

PROLeerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

PROWells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

PRORBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62

PROCitizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

PRO
Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

PRO
Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79